EWM
BMRN icon

Elite Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Elite Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-43
Closed -$3K – 360
2013
Q4 		$3K Buy
+43
New +$2.92K ﹤0.01% 563

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Elite Wealth Management's BMRN Position: Q1 2014 in Review

Elite Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2014, closing a stake of 43 shares — an estimated $3K sold.

Elite Wealth Management first reported a position in BMRN in Q4 2013 and held it in 1 quarter. The position peaked at $3K in Q4 2013. 313 funds tracked by Wall St. Rank hold BMRN as of Q1 2014.

  • Elite Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Elite Wealth Management sold 43 BioMarin Pharmaceuticals shares in Q1 2014, an estimated $3K.
  • Elite Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Elite Wealth Management's BioMarin Pharmaceuticals position peaked at $3K in Q4 2013.
  • 313 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2014.

Based on Elite Wealth Management's 13F filing for Q1 2014, filed 23 Nov 2016.